Valuation: Camurus AB

Market Cap 33.65B 3.46B 3.04B 2.8B 2.61B 4.92B 329B 5.02B 13.04B 162B 13B 12.72B 562B P/E 2026 *
37.5x
P/E 2027 * 19.9x
Enterprise Value 29.31B 3.02B 2.65B 2.44B 2.27B 4.28B 287B 4.37B 11.36B 141B 11.32B 11.08B 490B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 6.73x
Free-Float
64.67%
Yield 2026 *
-
Yield 2027 * -
1 week+4.57%
1 month+4.78%
3 months+21.55%
6 months-10.91%
Current year-10.91%
1 week 47.84
Extreme 47.84
52.05
1 month 42.72
Extreme 42.72
52.6
3 years 22.28
Extreme 22.28
67.55
5 years 11.16
Extreme 11.16
67.55
Manager TitleAgeSince
Chief Executive Officer 63 2002-12-31
Director of Finance/CFO 57 2025-06-30
Chief Tech/Sci/R&D Officer 58 2024-12-31
Director TitleAgeSince
Director/Board Member 63 2001-12-31
Chairman 77 2014-12-31
Director/Board Member 61 2020-05-06
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%+4.57%-6.67%+117.79% 3.47B
-1.65%+5.30%+51.63%+154.97% 1,070B
-0.38%+4.74%+61.89%+54.53% 611B
-0.32%+6.56%+31.74%+85.39% 445B
-3.05%+4.18%+31.11%+23.88% 329B
-1.74%-0.40%+33.19%+33.55% 290B
-1.25%+0.53%+27.68%+41.18% 287B
+2.99%+4.00%-26.09%-40.14% 213B
-0.89%+2.05%+23.44%+59.38% 195B
-0.36%+0.70%+12.81%+64.30% 157B
Average -0.61%+5.04%+24.07%+59.48% 399.58B
Weighted average by Cap. -0.90%+6.67%+37.77%+77.78%

Financials

2026 *2027 *
Net sales 2.81B 289M 254M 234M 218M 411M 27.48B 419M 1.09B 13.49B 1.09B 1.06B 46.95B 4.13B 424M 373M 343M 320M 603M 40.36B 615M 1.6B 19.81B 1.59B 1.56B 68.94B
Net income 897M 92.27M 81.01M 74.57M 69.49M 131M 8.77B 134M 348M 4.31B 346M 339M 14.99B 1.65B 170M 149M 138M 128M 242M 16.18B 247M 641M 7.94B 639M 625M 27.65B
Net Debt -4.34B -447M -392M -361M -336M -634M -42.46B -647M -1.68B -20.84B -1.68B -1.64B -72.54B -5.88B -605M -531M -489M -456M -859M -57.52B -877M -2.28B -28.23B -2.27B -2.22B -98.26B
Logo Camurus AB
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Employees
-
Date Price Change
26-07-01 52.00 +1.86%
26-06-30 €51.05 +2.18%
26-06-29 €49.96 +0.89%
26-06-26 €49.52 +0.28%
26-06-25 €49.38 +0.78%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
565.50SEK
Average target price
770.75SEK
Spread / Average Target
+36.30%

Quarterly revenue - Rate of surprise